New hope for hard-to-treat bowel cancer: targeted combo shows promise
NCT ID NCT07229846
First seen Nov 17, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests a new combination of drugs (aipalolitovorelizumab, bevacizumab, and chemotherapy) as a first treatment for people with advanced colorectal cancer that has a specific gene change called BRAF V600E. The goal is to see if this combo shrinks tumors and controls the disease. About 30 adults aged 18-75 will take part. The treatment is given through a vein and includes maintenance therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hosptital
Harbin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.